Modality
Multispecific
MOA
BCMA ADC
Target
SOS1
Pathway
STING
Atopic DermHeart Failure
Development Pipeline
Preclinical
~Dec 2013
→ ~Mar 2015
Phase 1
~Jun 2015
→ ~Sep 2016
Phase 2
~Dec 2016
→ ~Mar 2018
Phase 3
Jun 2018
→ Apr 2029
Phase 3Current
NCT07370717
1,755 pts·Atopic Derm
2018-07→2029-04·Recruiting
NCT04234698
188 pts·Heart Failure
2025-07→TBD·Active
NCT07396238
1,589 pts·Heart Failure
2021-01→2027-01·Completed
+1 more trial
3,822 total pts2 indications
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2027-01-1510mo awayPh3 Readout· Heart Failure
2029-04-123.0y awayPh3 Readout· Atopic Derm
Trial Timeline
Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2
P3
Not yet…
P3
Recruit…
P3
Complet…
P3
Active
Catalysts
Ph3 Readout
2027-01-15 · 10mo away
Heart Failure
Ph3 Readout
2029-04-12 · 3.0y away
Atopic Derm
RecruitingActiveCompletedNot yet recruiting|StartCompletionToday
Trials (4)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT07370717 | Phase 3 | Atopic Derm | Recruiting | 1755 | eGFR |
| NCT04234698 | Phase 3 | Heart Failure | Active | 188 | NT-proBNP |
| NCT07396238 | Phase 3 | Heart Failure | Completed | 1589 | OS |
| NCT03334001 | Phase 3 | Heart Failure | Not yet recr... | 290 | Mayo |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Terarelsin | AbbVie | Preclinical | SOS1 | |
| AZN-3724 | AstraZeneca | Preclinical | PSMA | |
| Ribofutibatinib | AstraZeneca | Phase 2/3 | SOS1 | |
| Olpatinib | GSK | Preclinical | PD-L1 | |
| GIL-9779 | Gilead Sciences | Phase 1 | IL-17A | |
| Voxacagene | Gilead Sciences | Phase 2/3 | SOS1 | |
| SRP-9822 | Sarepta | Phase 3 | SOS1 | |
| Sematenlimab | Samsung Biologics | Phase 3 | PI3Kα | |
| Fixaosocimab | TG Therapeutics | Phase 2/3 | SOS1 | |
| Zanurapivir | Immunocore | Phase 1 | SOS1 |